Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
Mark White, CEO of Nexalin Technology, remarked, “Securing this patent grant from the USPTO is a significant achievement for Nexalin as we continue to push the boundaries of non-invasive brain stimulation. Substance use disorders remain one of the ...